The AmplideX® PCR/CE DMPK Kit introduces a ground-breaking alternative for the detection and sizing of CTG repeats within the DMPK gene. Challenged by very large trinucleotide expansions, DMPK analysis has required the use of Southern blot technology, thereby limiting many laboratories’ ability to resolve these repeat sequences.
Leveraging the Repeat-Primed PCR (RP-PCR) in a simple, streamlined, PCR-only workflow, the AmplideX PCR/CE DMPK Kit can replace Southern blot technology and put DMPK analysis within the reach of laboratories everywhere.
Evidence supporting the functionality of this PCR kit has been published in scientific posters and discussed in depth at the European Society of Human Genetics conference 2018. VH Bio is pleased to offer these resources below.
A New Powerful PCR-Based Assay for the Molecular Diagnosis of Myotonic Dystrophy Type I
Author: Sophie Rondeau, PharmD, PhD, Medical Genetic Unit, Necker-Enfants Malades Hospital
Clinical correlations of a streamlined molecular assay based on AmplideX® PCR/CE technology that determines repeat size for both normal and expanded alleles in DMPK for myotonic dystrophy type 1
Author: Bradley Hall, Research and Development, Asuragen
RECORDED ESHG 2018 SYMPOSIUM
Evaluation of High Performing PCR-only AmplideX Workflow for Myotonic Dystrophy as a Replacement for Southern Blot
Dr Isabel Marques, Registered Clinical Laboratory Geneticist of Centro Hospitaldo Porto E.P.E., will share her experience with the new AmplideX PCR/CE DMPK Kit and how it represents a complete solution that eliminates the need for Southern blot analysis of this target.
Contact one of VH Bio’s technical specialists to hear about and see the data from the UK trial.